HOME >> MEDICINE >> NEWS
Studies demonstrate positive data in treatment of hepatitis C

BOSTON Data from two ongoing studies testing new approaches for the treatment of chronic hepatitis C will be presented at the annual meeting of the American Association for the Study of Liver Diseases (AASLD) this afternoon.

Presented by principal investigator Nezam Afdhal, M.D., Chief of Hepatology at Beth Israel Deaconess Medical Center (BIDMC) and Associate Professor of Medicine at Harvard Medical School, the new findings provide researchers with sufficient evidence to demonstrate promising results for hepatitis C patients who have not responded to existing therapies.

A viral infection, hepatitis C is transmitted through exposure to infected blood. The virus, which affects an estimated 4 million individuals nationwide, is able to survive and flourish inside the body by taking up residence in the liver cells, and subsequently using the cells' inner machinery to make more copies of the virus. These in turn, infect other healthy cells.

The standard treatment for hepatitis C is a combination of interferon alfa and ribavirin, which act as anti-viral agents to eradicate the virus. According to Afdhal, the most recent advance in treatment has been the pegylation of interferon, which enables a once- a- week administration of the protein by injection and improves the ability to clear the virus. Combination therapy with pegylated interferon plus ribavirin for 24 to 48 weeks can result in eradication of the virus in about 50 percent of patients, he adds.

"When the hepatitis C virus doesn't respond as occurs in about half of all patients who are treated those patients who already have cirrhosis are at a far greater risk for developing liver cancer or suffering liver failure," notes Afdhal. In fact, he says, hepatitis C is the leading cause of liver transplants in the U.S. Until now, no treatment has been available for these patients.

In his first presentation, Afdhal will describe results from the COPILOT [Colchicine versus PEG-INTRON Long-Term
'"/>

Contact: Bonnie Prescott
bprescot@bidmc.harvard.edu
617-667-7306
Beth Israel Deaconess Medical Center
1-Nov-2004


Page: 1 2 3

Related medicine news :

1. Studies underscore genetic involvement in nicotine addiction & aggressive hostility
2. Studies address issues of risk and survival in rapidly increasing GI cancers
3. Studies examine coffee drinking and risk of liver and colorectal cancers
4. Studies reveal physicians attitudes on end-of-life care
5. Studies from the November issue of The Archives of Dermatology, a theme issue on facial rejuvenation
6. Studies link obesity to increased frequency of heartburn symptoms; greater risk of esophageal cancer
7. Studies examine risk factors and potential consequences associated with prehypertension
8. Studies show ACTOS(R) (pioglitazone HCl) has positive effects on various components of dyslipidemia
9. Studies identify risk factors for colon cancer
10. Studies indicate healthy eating may affect cancer development, improve digestive system
11. Studies compare hysterectomy vs. other medical treatments for abnormal uterine bleeding

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/13/2019)... (PRWEB) , ... June 13, 2019 , ... ... company today announced that it has signed a memorandum of understanding (MOU) with ... its drug product MMJ-001 and MMJ-002. , MMJ BioPharma Cultivation will be supplying ...
(Date:6/13/2019)... ... 13, 2019 , ... Charm Sciences, Inc. is pleased to ... by the 2019 National Conference of Interstate Milk Shipments for screening milk tankers ... BL30SEC test was validated by third party laboratories working in collaboration with the ...
(Date:6/13/2019)... ... June 13, 2019 , ... Pure ... partnership with cannabis delivery company, Driven Deliveries, Inc., the only publicly traded cannabis ... 93% of the population of California with overnight cannabis delivery to major thriving ...
(Date:6/13/2019)... ... June 13, 2019 , ... ... proud to present the second annual Women|Future Conference and the advisory ... attendees to better position themselves and their organizations in tomorrow's marketplace. , The ...
(Date:6/13/2019)... ... 2019 , ... Kno2 ®, the company that provides ... the company’s CEO, has been confirmed by the membership body as a Director ... industry alliance created to support secure, identity-proofed electronic exchanges of personal health information ...
Breaking Medicine News(10 mins):
(Date:6/13/2019)... ... June 13, 2019 , ... ... has announced the new Smart Scheduling product, part of the HCHB Intelligence Suite, ... Scheduling product uses complex algorithms to create highly efficient routing, mapping and scheduling ...
(Date:6/13/2019)... ... June 13, 2019 , ... RxNT announced today that it has ... software solution . RxNT is a leader in healthcare technology solutions. This is the ... software users to highlight the best software products from North American small businesses. RxNT ...
(Date:6/13/2019)... ... June 13, 2019 , ... Tandigm Health , a ... appointment of Frank Ingari as President and Chief Operating Officer effective July 1, ... , With more than 35 years of experience serving the healthcare and ...
Breaking Medicine Technology:
Cached News: